Lead Product(s) : INF904
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
Details : INF904 is an orally administered low molecular weight C5aR inhibitor which is under clinical development for the treatment of chronic spontaneous urticaria & hidradenitis suppurativa.
Product Name : INF904
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2024
Lead Product(s) : INF904
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Scleroderma Research Foundation
Deal Size : Undisclosed
Deal Type : Partnership
The Scleroderma Research Foundation (SRF) Announces Second Partnership for Conquest Trial Platform
Details : Under the partnership, Boehringer Ingelheim will contribute an experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF to efficiently advance promising treatments for scleroderma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Scleroderma Research Foundation
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : HIBio
Deal Size : $1,015.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreements, HIBio will obtain exclusive rights to develop and commercialize MOR202 (felzartamab) and MOR210 across autoimmune and inflammatory disease, with the exception of Greater China for felzartamab and Greater China and South...
Product Name : MOR202
Product Type : Antibody
Upfront Cash : $15.0 million
June 14, 2022
Lead Product(s) : Felzartamab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : HIBio
Deal Size : $1,015.0 million
Deal Type : Licensing Agreement